The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.
about
Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infectionSelection of antitumor displayed peptides for the specific delivery of the anticancer drug lactaptinPhage protein-targeted cancer nanomedicines.Practical tips for construction of custom Peptide libraries and affinity selection by using commercially available phage display cloning systemsSelection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines.Trinucleotide cassettes increase diversity of T7 phage-displayed peptide library.Liposomes targeted by fusion phage proteinsDetermining glioma response to radiation therapy using recombinant peptides.Potential of phage-displayed peptide library technology to identify functional targeting peptidesPaclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity.Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein.In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein.Phage display and molecular imaging: expanding fields of vision in living subjects.Use of phage display technology for the determination of the targets for small-molecule therapeutics.Targeted delivery of siRNA into breast cancer cells via phage fusion proteins.Paclitaxel-loaded PEG-PE-based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce tumorsDelivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes.On the mechanism of targeting of phage fusion protein-modified nanocarriers: only the binding peptide sequence mattersConversion of low-affinity peptides to high-affinity peptide binders by using a β-hairpin scaffold-assisted approach.Exploration of Peptide Inhibitors of Human Squalene Synthase through Molecular Modeling and Phage Display Technique.Advancement and applications of peptide phage display technology in biomedical sciencePhage Peptide Libraries As a Source of Targeted Ligands.A new approach to quantification of mAb aggregates using peptide affinity probes.Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide.Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein.Engineered multifunctional nanocarriers for cancer diagnosis and therapeutics.Back to the future: bacteriophages as promising therapeutic tools.Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'.Identification of a specific peptide binding to colon cancer cells from a phage-displayed peptide library.Evolution of phage display: from bioactive peptides to bioselective nanomaterialsImmunocompatibility of Bacteriophages as Nanomedicines
P2860
Q26822719-52DBD5A5-8049-4A5D-9326-938F64CF2F25Q28468368-7D1A199C-BB2B-4274-B2A9-A0E07C301212Q30403553-B6D2865C-A07D-4FB3-AF74-435AB09931B5Q31093549-32D191A1-CB30-454F-B731-974D5BE8D97BQ31163147-033966FF-034D-46EC-839C-0B24C86446F0Q33301751-3A7B1D0B-F071-4E4D-A61C-FC967258C072Q33374206-D2E019AB-808E-4EFF-9568-628D0EE92B68Q33382467-3308775C-0D8E-4B23-AE55-0316E3E5F9BEQ33530848-5DBE8754-34AD-4555-998F-58CBCF45F122Q33592506-93490F60-7E81-4B93-AC23-B3590B1C884CQ33596415-CB51A53B-49F4-4917-A993-E4448548595FQ33806255-C7445646-C701-4D73-A8B4-3D6A3BA4CD15Q33849788-D592AB95-5F24-4CA7-BAE2-6B443F282307Q34347887-9933A23B-C6D2-4A9B-B3BC-4CD88E20C5A4Q34501858-CC021097-63BF-4224-9DF1-1B387CF126DBQ34647228-DEB60D69-7FF7-4077-B43B-FFA87E5EB6F3Q35024345-0D6AD983-FD23-4A75-91CD-AAA5E0AB74EDQ35256650-9E6DD701-769D-4295-9AFD-3C5A7CFE5AD9Q35394378-BC343BA8-02EF-4537-A71E-6B82CBF5BCDEQ35800044-6FD576BD-6DAF-470B-96E0-ED6B79AAECABQ35898339-491AD03C-DEEB-4789-B4F2-8364EFA60637Q35995567-8399FF01-0C9F-4E62-9531-C5A465642DA6Q36276715-A8ED683C-9F33-4B57-8679-75C5AFA8C5F8Q36687313-4520E4C8-E632-468C-A206-6736DA5302BBQ37624040-3BD9ED5F-30A3-4D41-B220-29E5E31226B6Q37885883-21A9AA73-8E9E-4608-BFD1-117D0F52CD8DQ38739669-9453C637-6C89-47B6-9E54-AF930BA49EDDQ38910806-CED06758-F75C-4FB0-AEE9-9E3F9FECA107Q47632555-60CE8B19-1570-41E8-83B8-0E13944FE41CQ56893922-3A5123DD-EAC3-45C5-9C19-31D16D9C62DFQ58910820-65807817-B6E7-4863-9200-0A6E918353B6
P2860
The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 March 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.
@en
The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.
@nl
type
label
The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.
@en
The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.
@nl
prefLabel
The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.
@en
The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.
@nl
P2860
P1476
The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.
@en
P2093
Lauren R H Krumpe
Toshiyuki Mori
P2860
P2888
P356
10.1007/S10989-005-9002-3
P577
2006-03-03T00:00:00Z